Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Accumulated Expenses (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Accumulated Expenses for 13 consecutive years, with $117000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Accumulated Expenses fell 88.15% to $117000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $117000.0, a 88.15% decrease, with the full-year FY2024 number at $117000.0, down 88.15% from a year prior.
  • Accumulated Expenses was $117000.0 for Q4 2024 at Plus Therapeutics, down from $987000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $989000.0 in Q4 2022 to a low of $117000.0 in Q4 2024.
  • A 4-year average of $707750.0 and a median of $862500.0 in 2020 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: rose 8.69% in 2020, then tumbled 88.15% in 2024.
  • Plus Therapeutics' Accumulated Expenses stood at $738000.0 in 2020, then skyrocketed by 34.01% to $989000.0 in 2022, then dropped by 0.2% to $987000.0 in 2023, then crashed by 88.15% to $117000.0 in 2024.
  • Per Business Quant, the three most recent readings for PSTV's Accumulated Expenses are $117000.0 (Q4 2024), $987000.0 (Q4 2023), and $989000.0 (Q4 2022).